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Abstract: BACKGROUND: This study validated a previously described diffusion-MRI phenotype as a
potential predictive imaging biomarker in patients with recurrent glioblastoma receiving bevacizumab
(BEV). METHODS: A total of 396/596 patients (66%) from the prospective randomized phase II/III
EORTC-26101 trial (with n=242 in the BEV and n=154 in the non-BEV arm) met the inclusion crite-
ria with availability of anatomical and diffusion MRI-sequences at baseline prior treatment. Apparent
diffusion coefficient (ADC) histograms from the contrast-enhancing tumor volume were fitted to a dou-
ble Gaussian distribution and the mean of the lower curve (ADClow) was used for further analysis.
The predictive ability of ADClow was assessed with biomarker threshold models and multivariable Cox-
regression for overall and progression-free survival (OS, PFS). RESULTS: ADClow was associated with
PFS (HR=0.625,p=0.007) and OS (HR=0.656,p=0.031). However, no (predictive) interaction between
ADClow and the treatment arm was present (p=0.865 for PFS, p=0.722 for OS). Independent (prog-
nostic) significance of ADClow was retained after adjusting for epidemiological, clinical and molecular
characteristics (p฀0.02 for OS, p฀0.01 PFS). The biomarker threshold model revealed an optimal ADClow
cutoff of 1241*10-6mm²/s for OS. Thereby, median OS for BEV-patients with ADClow฀1241 was 10.39
months vs. 8.09 months for those with ADClow<1241 (p=0.004). Similarly, median OS for non-BEV
patients with ADClow฀1241 was 9.80 months vs. 7.79 months for those with ADClow<1241 (p=0.054).
CONCLUSIONS: ADClow is an independent prognostic parameter for stratifying OS and PFS in pa-
tients with recurrent glioblastoma. Consequently, the previously suggested role of ADClow as predictive
imaging biomarker could not be confirmed within this phase II/III trial.
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In this study we validate a previously described diffusion-MRI phenotype as a potential 




MRI-data from the prospective randomized phase II/III EORTC-26101 trial in patients with first 
recurrence of glioblastoma were analyzed. A total of 396/596 patients (66%, with 242 in the 
BEV and 154 in the non-BEV treatment arm) met the inclusion criteria with availability of 
anatomical and diffusion MRI-sequences at baseline prior to treatment. The apparent diffusion 
coefficient (ADC) histograms from the contrast-enhancing tumor volume were fitted to a mixed 
model with a double Gaussian distribution and the mean of the lower curve (ADClow) was used 
for further analysis. The predictive ability of ADClow was assessed with biomarker threshold 
models and multivariable Cox-regression for OS and for progression-free survival (PFS).  
 
Results 
ADClow was associated with PFS (HR=0.625 [95%CI 0.445-0.880], p=0.007) and OS 
(HR=0.656 [95%CI 0.448-0.962], p=0.031). However, no (predictive) interaction between 
ADClow and the treatment arm was present (p=0.865 for PFS, p=0.722 for OS). Independent 
(prognostic) significance of ADClow was retained after adjusting for epidemiological, clinical and 
molecular characteristics (p≤0.02 for OS and ≤0.01 PFS). The biomarker threshold model 
revealed an optimal ADClow cutoff of 1241*10-6 mm²/s for OS. Thereby, median OS for BEV-
patients with ADClow<1241 was 10.39 months (95% CI, 9.4-15.55 months) vs. 8.09 months 
(95%CI, 7.1-9.53 months) for those with ADClow≥1241 (p=0.004). Similarly, median OS for non-
BEV patients with ADClow<1241 was 9.80 months (95%CI, 8.94-15.20 months) vs. 7.79 months 





ADClow is an independent prognostic parameter for stratifying OS and PFS in patients with 
recurrent glioblastoma. Consequently, the previously suggested role of ADClow as predictive 
imaging biomarker for benefit from BEV could not be confirmed within this randomized 





Glioblastoma remains one of the most aggressive forms of malignant primary brain tumor in 
adults [1]. Following standard treatment with maximal safe surgical resection, radiotherapy 
plus concomitant and maintenance temozolomide chemotherapy, almost all patients 
experience tumor progression. One commonly used treatment option at recurrence is 
bevacizumab (BEV), a humanized monoclonal antibody against vascular endothelial growth 
factor (VEGF) to block angiogenesis. BEV was approved for the treatment of recurrent 
glioblastoma by the US Food and Drug Administration (FDA) on the basis of two uncontrolled 
phase-II trials that demonstrated durable radiographic and, more importantly, clinical benefit in 
many patients [2, 3]. Although there is much support for the use of BEV, randomized phase-III 
trials (AVAglio, RTOG-0825, EORTC-26101) conducted to date have failed to show an overall 
survival (OS) benefit for BEV, both in the setting of newly-diagnosed [4, 5] and recurrent 
glioblastoma [6]. However, it seems to be reasonable to hypothesize that there may be 
subgroups of patient with a meaningful clinical therapy benefit and post-hoc analysis of the 
AVAglio trial suggested that the presence of a proneural molecular subtype is a predictive 
biomarker for stratifying BEV-treatment outcome in terms of OS [7]. However, there remains 
an unmet clinical need for easily, ideally non-invasively accessible, surrogate biomarkers able 
to delineate molecular activity and predict outcome to bevacizumab treatment [8-10]. Non-
invasive characterization of glioblastoma on magnetic resonance imaging (MRI) has shown 
great potential for therapy guidance and previous studies indeed suggested that patients with 
a specific phenotype on diffusion MRI may derive a significant OS benefit from BEV treatment 
[11-15]. Specifically, histogram analysis of apparent diffusion coefficient values (ADC) from 
diffusion MRI with fitting of a double Gaussian mixed model and quantification of the mean 
ADC from the lower curve (ADClow) has been suggested as a potential predictive imaging 
biomarker for stratifying BEV-treatment outcome in terms of OS, both in the setting of newly 
diagnosed [14, 15] and recurrent glioblastoma [11-13]. However, despite these intriguing 
findings the utility of ADClow as a truly predictive imaging biomarker has not yet been fully 
established, since available studies are based on the analysis of retrospective datasets [12-
 
 
15] or post-hoc analysis of available phase II trials [11]. Specifically, data from randomized 
phase III trials with availability of a BEV-free control arm would be necessary to reliable 
differentiate whether ADClow is a truly predictive biomarker (and allows to identify the likelihood 
of sensitivity to BEV treatment) or whether it only serves as a prognostic biomarker (and thus 
reflects the patients overall outcome, regardless of therapy) [16].  
Here we performed an exploratory post-hoc analysis of the randomized controlled multicentre 
phase II and III EORTC-26101 trial (NCT01290939) in patients with first recurrence of 
glioblastoma. Specifically, we assessed whether ADClow quantified from baseline MRI prior to 
treatment is a prognostic and/or predictive imaging biomarker for stratifying treatment 





Study design and participants 
For the present study we analyzed MRI data from brain tumor patients acquired as part of the 
European Organisation for Research and Treatment of Cancer (EORTC) 26101 trial 
(NCT01290939). As described previously [17], the EORTC-26101 study was a prospective 
randomized phase II and III trial in patients with first progression of a glioblastoma after 
standard chemo-radiotherapy. In brief, the phase II trial evaluated the optimal treatment 
sequence of bevacizumab and lomustine (four treatment arms with single agent vs. sequential 
vs. combination) whereas the subsequent phase III trial (two treatment arms) compared 
patients treated with lomustine alone with those receiving a combination of lomustine and 
bevacizumab. Overall, the EORTC-26101 study included 596 patients (n=159 from phase II 
and n=437 from phase III) at 37 institutions within Europe. The study was conducted in 
accordance with the Declaration of Helsinki and the protocol was approved by local ethics 
committees and patients provided written informed consent (EudraCT# 2010-023218-30). Full 
study design and outcomes have been published previously 7, 16. MRI exams were acquired 
with a standardized imaging protocol with acquisition of pre- and postcontrast T1-weighted, 
T2-weighted and FLAIR images at baseline and every 6 weeks until week 24, afterwards every 
3 months according to a prespecified MR protocol [18]. In addition, optional acquisition of 
diffusion-weighted MRI (DWI) was performed at the discretion of the individual institution.  
Based on the four treatment arms of the phase II trial and the two treatment arms in the phase 
III trial patients were allocated for the present post-hoc analysis into two groups (a) those 
receiving bevacizumab (BEV subgroup) and, (b) those not receiving bevacizumab (non-BEV 
subgroup) for the treatment at first recurrence of glioblastoma. Specifically, the BEV subgroup 
consisted of patients that were allocated to the bevacizumab plus lomustine treatment arm (at 
progression salvage treatment at the investigators best choice) or the bevacizumab alone 
treatment arm (at progression switch to bevacizumab plus lomustine), whereas the non-BEV 
subgroup consisted of patients that were allocated to the lomustine alone treatment arms (at 
 
 
progression either switch to bevacizumab or salvage treatment at the investigators best 
choice). 
Sample size for the present analysis was determined by the availability of MRI data and not 
derived from a power calculation. Specifically, we required MRI examinations that included (a) 
anatomical sequences (pre- and postcontrast T1-weighted [T1-w, cT1-w], T2-weighted [T2-w] 
and FLAIR images) and (b) DWI or ADC sequences at baseline prior treatment. We excluded 
those MRI examinations with (a) corrupt data following DICOM to NIfTI conversion (primarily 
due to the non-standardized center-specific anonymization of DICOM-files), (b) incomplete 
availability of T1-w, cT1-w, FLAIR, T2-w and DWI or ADC sequences (requiring either 3D 
acquisitions or 2D with axial orientation), (c) heavy motion artifacts, or (d) insufficient contrast-
agent administration during cT1-w acquisition.  
Procedures 
The ADC sequences were supplied by the individual institution (calculated on-the-fly by the 
scanner software). For those cases with missing ADC but available DWI, we generated ADC 
maps from DWI using dedicated software (Olea Sphere v 2.3, Olea Medical, La Ciotat, France). 
Next, processing of the anatomical sequences (T1-w, cT1-w, T2-w and FLAIR) was performed 
as described previously [19, 20] and included automated deep-learning based brain extraction 
[20] followed by registration of the brain-extracted cT1-w, FLAIR, T2-w image volumes to the 
respective brain extracted T1-w image volume using the linear image registration tool (FMRIB 
software library, FSL, http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FSL) with spline interpolation and a 6-
degree of freedom transformation. Subsequently automated deep-learning based voxel-wise 
segmentation and volumetric quantification of the contrast-enhancing tumor volume was 
performed [19]. Next, the binary brain mask from the T1-w image volume was transferred to 
the ADC image volumes, followed by registration of the brain-extracted ADC image volumes 
to the respective brain extracted T1-w image volume using the linear image registration tool 
(FMRIB software library, FSL, http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FSL) with spline interpolation 
and a 6-degree of freedom transformation. The transformation matrix that was generated 
 
 
during registration of the brain-extracted ADC to the brain-extracted T1-w image volume was 
inverted and applied to the tumor segmentation mask. Thereby, the tumor segmentation mask 
was transformed to the original (non-registered) image space of the ADC sequence using 
nearest neighbor interpolation.  
Subsequent processing was done using MATLAB R2018a (The MathWorks, Inc., Natick, 
Massachusetts, United States). First, extraction of ADC values within the contrast-enhancing 
tumor segmentation mask of the original (non-registered) ADC sequence was performed and 
all extracted ADC values were used to construct the histogram. An automatic binning algorithm 
was used to determine the optimal number and width of the bins. A two-term Gaussian model 
with a robust non-linear least square fitting method and a trust-region algorithm was applied 
by using the Curve Fitting Toolbox (ver. 3.5.5). We defined the following fitting options: (1) 
constraining the lower bounds on the coefficients, specifically the peaks to 1 voxel and the 
means of the Gaussian curves to the lowest voxel value in the contrast-enhancing tumor 
segmentation mask, (2) constraining the upper bound on the coefficients, specifically the peaks 
to the number of voxel within the mask and the means to highest voxel value in the contrast-
enhancing tumor segmentation mask, (3) determine the starting points of the lower centroid at 
the 25th and upper centroid at the 75th percentile. The goodness of fit was evaluated with R2 
and through visual inspection of the residuals (cases with R2 values <0.7 were excluded from 
further analysis). No further manual parameter adjustments were applied. The mean of the 
lower Gaussian curve (ADClow) was used for subsequent statistical analysis. Figure 1 illustrates 
the workflow in a representative case.  
Outcomes 
The objective of the present study was to identify whether ADClow is a prognostic and/or 
predictive imaging biomarker for stratifying treatment outcome (by means of PFS and OS) to 
BEV therapy in patients with recurrent glioblastoma.  OS was calculated from the date of 
randomization until death or last follow-up. PFS was calculated from the date of randomization 
until the date of tumor progression (as assessed by local RANO reading as part of the initial 




Statistical analysis was performed with R version 3.6.2 (R Foundation for Statistical 
Computing, Vienna, Austria). The distribution of baseline clinical, molecular and imaging 
characteristics between the BEV and non-BEV groups was compared with the chi-square test 
for categorical parameters and the Wilcoxon rank sum test for continuous parameters.  
The potential predictive association between ADClow and the effect of BEV was evaluated by 
constructing predictive biomarker threshold models. ADClow was fitted using a hierarchical 
Bayesian method under the framework of the Cox proportional hazards model separately for 
OS and PFS (implemented with the bhm package in R [https://cran.r-
project.org/web/packages/bhm] using standard parameters i.e. with B=500 burn-in steps and 
R=2000 replications for the Bayesian method as recommended by the developers for the 
analysis of a biomarker variable) [21]. The hierarchical Bayesian method simultaneously 
makes a statistical inference on the ADClow threshold defining the sensitive patient subset and 
the interaction effect in terms of outcome (OS or PFS) between ADClow and the treatment (i.e. 
BEV vs. non-BEV subgroup). 
Multivariable Cox proportional hazards regression modeling with the continuous ADClow value 
for both OS and PFS was separately performed for the BEV and non-BEV groups. The model 
was adjusted for potential clinical confounders (age, sex, WHO performance status, 
glucocorticoid administration at randomization, sequence of treatment), molecular 
confounders (O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status, 
glioma-CpG island methylator phenotype (GCIMP) status)) and baseline contrast-enhancing 
tumor volume. The Kaplan-Meier method with the log-rank test was used to construct survival 
curves for OS and PFS in both BEV and non-BEV subgroups (and grouping patients based on 
the cut-off determined by the biomarker threshold model for  ADClow value). The association 
between ADClow values and MGMT promotor methylation status was examined with the 
Wilcoxon rank sum test. P-values <0.05 were considered significant.  
Role of the funding source 
 
 
The funders of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. MS, MB and PK had full access to all the data in the 




Out of 596 patients in the EORTC-26101 phase II and III study, a subset of 396 patients 
(66.4%) met the outlined criteria for this post-hoc analysis (see Figure 2). Specifically, the 396 
patients included 242 patients (61.1%) in the BEV subgroup and 154 patients (38.9%) in the 
non-BEV subgroup. Baseline clinical characteristics (sex, age, WHO performance status, use 
of glucocorticoids, sequence of treatment), molecular characteristics (MGMT promoter 
methylation status, GCIMP status) and contrast-enhancing tumor volumes were equally 
distributed between the BEV and non-BEV subgroup (Table 1). The ADClow values were 
balanced with a median of 1027*10-6 mm²/s for the BEV subgroup and 1125*10-6 mm²/s for the 
non-BEV subgroup (p=0.46, see Table 1). Moreover, R2 (as a measure of goodness-of-fit) 
showed no difference between the groups, resulting in an unbiased fitting result for the 
comparison (p=0.998) (see Supplementary Table S1).  
PFS was longer in the BEV group (3.98 months [95% CI, 3.22-4.21 months]) than in the non-
BEV group (1.55 months [95% CI, 1.48-2.60 months], p<0.0001), whereas OS was not 
different between the BEV group (8.91 months [95% CI, 7.99-9.96 months]) and the non-BEV 
group (8.61 months [95% CI, 7.76-9.80 months], p=0.95) (see Figure 3). The biomarker 
threshold models demonstrated that ADClow was significantly associated with both PFS 
(HR=0.625 [95% CI 0.445-0.880], p=0.007) and OS (HR=0.656 [95% CI 0.448-0.962], 
p=0.031). However, no (predictive) interaction between ADClow and the treatment arm was 
present, neither for PFS (HR=1.04 [95% CI 0.66-1.63], p=0.865) nor for OS (HR=0.91 [95% CI 
0.54-1.54], p=0.7221) (see Table 2). Multivariable Cox-regression modeling confirmed the 
independent (prognostic) significance of ADClow after adjusting for epidemiological, clinical and 
molecular characteristics (p≤0.02 for OS and ≤0.01 PFS) (see Figure 4).  
The biomarker threshold model revealed an optimal ADClow cutoff of 1241*10-6 mm²/s for OS 
(corresponding to a 75:25 split of the dataset, see Table 2). By applying this cutoff, the median 
OS for BEV-patients with ADClow<1241 was 10.39 months (95% CI, 9.4-15.55 months) vs. 8.09 
months (95% CI, 7.1-9.53 months) for those with ADClow>1241 (p=0.004) (see Figure 5). 
Kommentiert [WM1]: Reicht nicht eine Stelle hinter dem 
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Similarly, median OS for non-BEV patients with ADClow<1241 was 9.80 months (95%CI, 8.94-
15.20 months) vs. 7.79 months (95%CI, 6.15-9.50 months) for those with ADClow>1241 
(p=0.054) (see Figure 5). For PFS the biomarker threshold model revealed an optimal ADClow 
cutoff of 1217*10-6 mm²/s (corresponding to a 70:30 split of the dataset, see Table 2). By 
applying this cutoff, the median PFS for BEV-patients with ADClow<1241 was 5.38 months 
(95% CI, 4.21-6.58 months) vs. 3.29 months (95% CI, 2.89 – 4.14 months) for those with 
ADClow>1241 (p=0.003) (see Figure 5). Similarly, median PFS for non-BEV patients with 
ADClow<1241 was 2.73 months (95% CI, 1.55-4.21 months) vs. 1.48 months (95% CI, 1.45-
1.64 months) for those with ADClow>1241 (p=0.021) (see Figure 5). 
There was no association between ADClow and MGMT promoter methylation status (p=0.13) 
(see Figure 6). Specifically, median ADClow values were 1124*10-6 mm²/s (IQR, 985*10-6 mm²/s 
- 1280*10-6 mm²/s) for MGMT promoter-methylated and 1085*10-6 mm²/s (IQR, 951*10-6 mm²/s 
- 1233*10-6 mm²/s) for MGMT promoter-unmethylated tumors.  
  
Kommentiert [WM3]: MGMT could also go to the 





Non-invasive characterization of glioblastoma on MRI has been extensively used for studying 
the effects of BEV and for attempting non-invasive identification of patient subsets for whom 
anti-angiogenic treatment may be beneficial [11, 22, 23]. In this context, the discovery of 
ADClow as a potential predictive imaging biomarker for stratifying both PFS and OS has gained 
significant interest [11-15]. Specifically, initial studies obtained from retrospective datasets 
demonstrated that both newly diagnosed as well as recurrent glioblastoma patients with lower 
ADClow levels exhibit a more durable response from BEV, both in terms of PFS and OS [12-
15]. Subsequent post-hoc analysis of the randomized controlled phase II BELOB trial 
confirmed these earlier findings [11]. In particular, the BELOB trial compared the use of single-
agent bevacizumab vs. lomustine vs. a combination of bevacizumab plus lomustine [24]. 
ADClow was significantly associated with OS in patients treated with single-agent BEV but not 
in those with single-agent lomstine; no results were shown for the combination arm of 
bevacizumab plus lomustine [11]. Based on these results it was suggested that ADClow is a 
predictive imaging biomarker and allows to identify the likelihood of sensitivity to BEV treatment 
[11]. However, despite these intriguing findings, confirmatory evidence from phase III trials is 
lacking [4-6]. In the present post-hoc analysis of the randomized controlled multicentre phase 
II and III EORTC-26101 trial we therefore aimed to validate the utility of ADClow as a predictive 
imaging biomarker. By applying a robust post-processing workflow, we found that ADClow was 
significantly associated with PFS and OS, however no (predictive) interaction between ADClow 
and treatment group (BEV vs. non-BEV) was present. Consequently, these findings challenge 
previous studies and suggest that ADClow serves as a prognostic biomarker and thus reflects 
the patient’s overall outcome, regardless of therapy in the setting of recurrent glioblastoma. 
One could argue that the lack of predictive association between ADClow and BEV-treatment in 
terms of OS within the scope of the EORTC-26101 trial was confounded by cross-over 
between treatment arms. Specifically, cross-over was seen in 35% of patients within the non-
BEV subgroup who received BEV treatment following disease progression. Nevertheless, this 
effect may have been negligible given the identical (prognostic) pattern that was found for 
 
 
ADClow also in terms of PFS (which was not affected by any cross-over). Moreover, the 
sequence of treatment had no independent significance on multivariable Cox regression 
modeling. The cut-offs for ADClow that were suggested by the biomarker threshold model (OS: 
1241*10-6 mm²/s and PFS: 1217*10-6 mm²/s) were comparable to previous works that obtained 
cutoffs of 1200*10-6 mm²/s [12-15] and 1240*10-6 mm²/s [11], implying a robust extraction 
independent of scanner hardware and extraction software. A possible explanation for the 
prognostic effect of ADClow would be the well-known association of tumor cellularity and ADC 
[25, 26]. Lower ADC values are associated with a higher cellularity and higher tumor burden 
[27-29], which could explain a prognostic effect of ADClow independent of treatment [30-32]. In 
contrast, mechanism of ADClow as a predictive biomarker for BEV remain speculative and 
unclear [11].  
Given the prognostic importance of ADClow and MGMT promoter methylation status, we 
specifically investigated their relationship, since previous studies suggested lower ADClow 
values for newly-diagnosed MGMT-methylated glioblastoma Pope, Lai [15] whereas other 
studies showed no association between ADC measurements and MGMT status [33-35]. Our 
study also did not show any association between ADClow and MGMT promoter methylation 
status, thereby suggesting that ADClow and MGMT status contribute to prognosis of recurrent 
glioblastoma through independent mechanisms with additive prognostic effects. 
Our study has some limitations. First, we acknowledge that only a subset of 396 of 596 patients 
(66%) met the criteria for this post-hoc analysis with sample size determined by the availability 
of MRI data and not derived from a power calculation. Second, we could not perform central 
standardized calculation of ADC sequences for all analyzed patients, but instead relied on the 
ADC sequences that were generated on-the-fly by the scanner software of the individual 
institutions for most cases. This may have led to a non-standardized generation of ADC 
sequences due to different scanner software. However, the applied ADC histogram analysis 
has proven to be a very robust method with high reproducibility [36]. Third, the information on 
b-values used for acquiring the DWI sequences was missing for most cases (due to routine 
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anonymization of relevant DICOM tags in multicenter studies). For those cases with available 
information on B-values we noted that acquisition was either performed with b=1000 or 
b=1200. Although it is well known that increasing b-values shift the ADC histograms to lower 
values it remains unlikely that this was a relevant confounder for not identifying a predictive, 
but only a prognostic association of ADClow within the EORTC-26101 trial. 
In conclusion, ADClow is an independent prognostic parameter for stratifying OS and PFS within 
the scope of the EORTC-26101 trial in patients with recurrent glioblastoma. Consequently, the 
previously suggested role of ADClow as predictive imaging biomarker was not confirmed. 
Overall, identifying patient subsets that may benefit from BEV remains challenging and the 
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    Sex — no. (%) 
       Female 95 (39) 54 (35) 
0.46 
       Male 147 (61) 400 (65) 
    Age — yr.  
       Median 58 60 
0.24 
       Interquartile range 51, 65 52, 66 
    WHO performance status — no. (%) 
       0 79 (33) 51 (33) 
1.00 
       ≥1 163 (67) 101 (67) 
    Use of glucocorticoids — no. (%) 
       No 112 (46) 79 (51) 
0.38 
       Yes 130 (54) 75 (49) 
    Sequence of treatment — no. (%) 
       BEV (at PD: BEV+LOM) 54 (22) - 
n.a. 
       BEV+LOM (at PD investigators choice) 188 (78) - 
       LOM (at PD: BEV) - 54 (35) 
       LOM (at PD investigators choice) - 100 (65) 
Molecular characteristics 
    MGMT promoter methylation status — no. (%) 
       Methylated 74 (31) 54 (35) 
0.65        Unmethylated 77 (32) 46 (30) 
       Undetermined / Missing data 91 (38) 54 (35) 
    GCIMP status — no. (%) 
       Positive 5 (2) 7 (5) 
0.27 
       Negative 237 (98) 147 (95) 
Quantitative MRI parameters at baseline MRI 
    Contrast-enhancing tumor volume (cm³)  
       Median 15.38 17.93 
0.25 
       Interquartile range  6.80, 29.58 8.70, 32.43 
    ADClow (10-6 mm²/s)  
       Median 1078 1125 
0.46 
       Interquartile range  954, 1229 987, 1272 
 
Abbreviations: ADC=apparent diffusion coefficient, BEV=bevacizumab, LOM=lomustine, 
PD=progressive disease, G-CIMP = glioma-CpG island methylator phenotype, MGMT = O6-






Table 2: Results of biomarker threshold model for overall survival (OS) and progression free 
survival (PFS). The cutoff refers to the optimal threshold suggest by the model. HR=hazard 
ratio.  
 Parameter HR (95% CI) P-value Cut-off 
OS ADClow 0.656 (0.448-0.962) 0.031 
1241*10-6 
mm²/s 
Treatment 0.984 (0.757-1.280) 0.905 
ADClow:Treatment* 0.909 (0.537-1.538) 0.722 
PFS ADClow 0.625 (0.445-0.880) 0.007 
1217*10-6 
mm²/s 
Treatment 0.517 (0.402-0.666) <0.001 
ADClow:treatment* 1.040 (0.662-1.634) 0.865 
 





Figure 1. Processing pipeline for a representative patient. (A) original MR images (axial slice 
of contrast-enhanced T1-weighted, T1-weighted, T2-weighted and FLAIR image). (B) brain-
extracted, contrast-enhanced T1-weighted image with mask of contrast-enhanced lesion (light 
blue). (C) ventral and lateral view of surface rendering with 3D contrast-enhanced lesion mask. 
(D) non-registered ADC map with applied contrast-enhanced lesion mask (light blue). (E)  
extracted histogram of ADC values with individual Gaussian curves (white broken line) and the 





Figure 2. Flowchart of the procedures and analysis performed within the present study. 
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Figure 3. Kaplan-Meier plots for overall survival (OS, left panel) and progression free-survival 
(PFS, right panel) comparing BEV vs. non-BEV groups. Treatment with BEV was associated 
with longer PFS (p<0.001) but not OS (p=0.951). 
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Figure 4. Multivariable Cox proportional hazards regression model for overall survival (OS, left panel) and progression free-survival (PFS, right 
panel) in BEV treated patients (upper panel) and non-BEV treated patients (lower panel). Independent significance of ADClow was retained after 
adjusting for epidemiological, clinical and molecular characteristics. 
 




Figure 5. Kaplan-Meier plots for overall survival (OS, 1st row) and progression free-survival 
(PFS, 2nd row) stratifying based on their ADClow value on baseline MRI. Patients with ADClow 
values above the cut-off identified by the biomarker threshold model (≥1241*10-6 mm²/s for OS 
and ≥1217*10-6 mm²/s for PFS) demonstrated significantly longer PFS and OS as compared 
to patients with ADClow values below the cut-off. This effect was seen for both BEV-subgroup 
(left column) and non-BEV subgroup (right column), thereby confirming that ADClow is a 
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Figure 6. Relationship between ADClow and MGMT promoter methylation status assessed with 
relative frequency histogram of ADClow values according to MGMT status (left panel) and 
boxplots (right panel). Median ADClow values were 1141*10-6 mm²/s for MGMT-methylated and 





Data Supplement  
 
Supplementary Table S1. Image acquisition parameters related to apparent diffusion 
coefficient (ADC) sequences as well as corresponding ADC histogram fits, comparing BEV 










    GE 101 (43) 57 (27) 
0.27 
    Philips 51 (22) 29 (19) 
    Siemens 84 (36) 66 (43) 
    Toshiba 0 (0) 1 (1) 
Field strength 
    1.5 T 67 (30) 52 (35) 
0.50     3.0 T 49 (22) 31 (21) 
    1.5 or 3 T 111 (49) 65 (44) 
ADC resolution 
    In plane resolution (mm)   
0.40         Median 0.94 0.98 
        Interquartile Range (IQR) 0.94, 1.25 0.94, 1.25 
    Slice thickness (mm)    
0.14         Median 5.00 5.00 
        Interquartile Range (IQR) 5.00, 5.00 5.00, 5.00 
B-values 
    1000 71 (29) 61 (40) 
0.09     1200  6 (2) 2 (1) 
    Unknown  165 (68) 91 (59) 
Histogram fit 
    Adjusted R²   
0.64         Median 0.99 0.99 
        Interquartile Range (IQR) 0.98, 0.99 0.97, 0.99 
    Width of bins (*10-6 mm²/s)   
1.00         Median 100 100 
        Interquartile Range (IQR) 50, 100 50, 100 
 
 
 
